Press Release: Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban) Friday, December 28, 2012 5:46 pm EST PRINCETON, N.J. & NEW YORK--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved ELIQUIS® (apixaban). Please see full Prescribing Information including BOXED WARNING and Medication Guide …
Read MoreArchives
The Food and Drug Administration (FDA) approved the AtriCure Synergy Ablation System for the treatment of persistent and longstanding persistent atrial fibrillation in patients undergoing another heart surgery. The Synergy bipolar radiofrequency clamp is the only surgical ablation device with FDA approval for afib treatment. Learn more: FDA Advisory Panel Recommends, and FDA Approves, Bipolar …
Read MoreWe recently reported that an ablation catheter clinical trial would potentially usher in FDA approval of the first device for treating atrial fibrillation. That approval was just granted today when the NAVISTAR® THERMOCOOL® Catheter from Biosense Webster (Johnson & Johnson) was approved by the FDA for catheter ablation of atrial fibrillation. Finally, a step in …
Read MoreOne of the many studies reported on this week at the American Heart Association Scientific Sessions in New Orleans was about an ablation catheter clinical trial (from Biosense Webster) that may finally usher in the first FDA approval of a device for treating atrial fibrillation. Read why this could be good news for anyone with …
Read More